{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:22:25Z","timestamp":1792207345006,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neuroblastoma is the most common extracranial solid tumor found in children and survival rate is extremely meager. HDAC8, a class I zinc-dependent enzyme, is a potential drug target for treatment of neuroblastoma and T cell lymphoma. Most of the HDAC8 inhibitors discovered till date contains a hydroxamic acid group which acts as a zinc binding group. The high binding affinity to the zinc and other ions results in adverse effects. Also, the non-selective inhibition of HDACs cause a variety of side effects. The objective of this is to identify structurally diverse, non-hydroxamate, novel, potential and selective HDAC8 inhibitors. A number of five featured pharmacophore hypotheses were generated using 32 known selective HDAC8 inhibitors. The hypotheses ADDRR.4 were selected for building 3D QSAR model. This model has an excellent correlation coefficient and good predictive ability, which was employed for virtual screening of Phase database containing 4.3\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> molecules. The resultant hits with fitness score &gt;1.0 were optimized using in-silico ADMET (absorption, distribution, metabolism, \u00a0excretion, and toxicity) and XP glide docking studies. On the basis of pharmacophore matching, interacting amino acid residues, XP glide score, more affinity towards HDAC8 and less affinity towards other HDACs, and ADME results five hits- SD-01, SD-02, SD-03, SD-04 and SD-05 with new structural scaffolds, \u00a0non-hydroxamate were selected for <jats:italic>in vitro<\/jats:italic> activity study. SD-01 and SD-02 were found to be active in the nanomolar (nM) range. SD-01 had considerably good selectivity for HDAC8 over HDAC6 and SD-02 had marginal selectivity for HDAC6 over HDAC8. The compounds SD-01 and SD-02 were found to inhibit HDAC8 at concentrations (IC<jats:sub>50<\/jats:sub>) 9.0\u2009nM and 2.7\u2009nM, respectively.<\/jats:p>","DOI":"10.1038\/s41598-019-53376-y","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T11:04:02Z","timestamp":1574247842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation"],"prefix":"10.1038","volume":"9","author":[{"given":"Sudhan","family":"Debnath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanusree","family":"Debnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samhita","family":"Bhaumik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapan","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5948-2337","authenticated-orcid":false,"given":"Arunasree M.","family":"Kalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vema","family":"Aparna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"key":"53376_CR1","doi-asserted-by":"publisher","first-page":"7489","DOI":"10.18632\/oncotarget.9841","volume":"8","author":"LT Wang","year":"2017","unstructured":"Wang, L. T. et al. Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma. Oncotarget. 8, 7489\u20137501, https:\/\/doi.org\/10.18632\/oncotarget.9841 (2017).","journal-title":"Oncotarget."},{"key":"53376_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","volume":"13","author":"KJ Falkenberg","year":"2014","unstructured":"Falkenberg, K. J. & Johnstone, R. W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 13, 673\u2013691, https:\/\/doi.org\/10.1038\/nrd4360 (2014).","journal-title":"Nat Rev Drug Discov."},{"key":"53376_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21767\/2472-1158.100015","volume":"2","author":"C Zwergel","year":"2016","unstructured":"Zwergel, C., Stazi, G., Valente, S. & Antonello, M. Histone Deacetylase Inhibitors: Updated Studies in Various Epigenetic-Related Diseases. J Clin Epigenet. 2, 1\u201315, https:\/\/doi.org\/10.21767\/2472-1158.100015 (2016).","journal-title":"J Clin Epigenet."},{"key":"53376_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.tips.2015.04.013","volume":"36","author":"A Chakrabarti","year":"2015","unstructured":"Chakrabarti, A. et al. HDAC8: a multifaceted target for therapeutic interventions. Trends Pharmacol. Sci. 36, 481\u2013492, https:\/\/doi.org\/10.1016\/j.tips.2015.04.013 (2015).","journal-title":"Trends Pharmacol. Sci."},{"key":"53376_CR5","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1517\/14728220903241658","volume":"18","author":"I Oehme","year":"2009","unstructured":"Oehme, I., Deubzer, H. E., Lodrini, M., Milde, T. & Witt, O. Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin. Investig. Drugs. 18, 1605\u20131617, https:\/\/doi.org\/10.1517\/14728220903241658 (2009).","journal-title":"Expert Opin. Investig. Drugs."},{"key":"53376_CR6","doi-asserted-by":"publisher","first-page":"8026","DOI":"10.1021\/jm5008962","volume":"57","author":"G Tang","year":"2014","unstructured":"Tang, G. et al. Identification of a Novel Aminotetralin Class of HDAC6 and HDAC8 Selective Inhibitors. J. Med. Chem. 57, 8026\u20138034, https:\/\/doi.org\/10.1021\/jm5008962 (2014).","journal-title":"J. Med. Chem."},{"key":"53376_CR7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R. & Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. The Oncologist. 12, 1247\u20131252, https:\/\/doi.org\/10.1634\/theoncologist.12-10-1247 (2007).","journal-title":"The Oncologist."},{"key":"53376_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00280-013-2220-z","volume":"72","author":"M Iwamoto","year":"2013","unstructured":"Iwamoto, M. et al. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother. Pharmacol. 72, 493\u2013508, https:\/\/doi.org\/10.1007\/s00280-013-2220-z (2013).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"53376_CR9","doi-asserted-by":"publisher","unstructured":"FDA, Office of Oncology Drug Products. \u201cWhat\u2019s New from the Office of Oncology Drug Products\u201d http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/CDER\/ucm093885.htm, https:\/\/doi.org\/10.1093\/jnci\/djq030 (2010).","DOI":"10.1093\/jnci\/djq030"},{"key":"53376_CR10","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1517\/13543784.2011.594437","volume":"20","author":"EM Bertino","year":"2011","unstructured":"Bertino, E. M. & Otterson, G. A. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin. Investig. Drugs. 20, 1151\u20131158, https:\/\/doi.org\/10.1517\/13543784.2011.594437 (2011).","journal-title":"Expert Opin. Investig. Drugs."},{"key":"53376_CR11","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","volume":"21","author":"HZ Lee","year":"2015","unstructured":"Lee, H. Z. et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin. Cancer Res. 21, 2666\u20132670, https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3119 (2015).","journal-title":"Clin. Cancer Res."},{"key":"53376_CR12","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","volume":"21","author":"JP Laubach","year":"2015","unstructured":"Laubach, J. P., Moreau, P., San-Miguel, J. F. & Richardson, P. G. Panobinostat for the Treatment of Multiple Myeloma. Clin Cancer Res. 21, 4767\u201373, https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0530 (2015).","journal-title":"Clin Cancer Res."},{"key":"53376_CR13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.leukres.2012.03.003","volume":"36","author":"A Quint\u00e1s-Cardama","year":"2012","unstructured":"Quint\u00e1s-Cardama, A. et al. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leukemia Res. 36, 1124\u20131127, https:\/\/doi.org\/10.1016\/j.leukres.2012.03.003 (2012).","journal-title":"Leukemia Res."},{"key":"53376_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5582\/irdr.2016.01024","volume":"5","author":"X Lu","year":"2016","unstructured":"Lu, X., Ning, Z., Li, Z., Cao, H. & Wang, X. Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. Intractable Rare Dis. Res. 5, 185\u2013191, https:\/\/doi.org\/10.5582\/irdr.2016.01024 (2016).","journal-title":"Intractable Rare Dis. Res."},{"key":"53376_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-8722-3-5","volume":"3","author":"J Tan","year":"2010","unstructured":"Tan, J., Cang, S., Ma, Y., Petrillo, R. L. & Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 3, 1\u201313, https:\/\/doi.org\/10.1186\/1756-8722-3-5 (2010).","journal-title":"J Hematol Oncol."},{"key":"53376_CR16","doi-asserted-by":"publisher","first-page":"8139","DOI":"10.1021\/bi400740x","volume":"52","author":"RK Singh","year":"2013","unstructured":"Singh, R. K. et al. Kinetic and thermodynamic rationale for suberoylanilide hydroxamic acid being a preferential human histone deacetylase 8 inhibi tor as compared to the structurally similar ligand, trichostatin a. Biochemistry. 52, 8139\u20138149, https:\/\/doi.org\/10.1021\/bi400740x (2013).","journal-title":"Biochemistry."},{"key":"53376_CR17","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1016\/j.bmcl.2007.02.064","volume":"17","author":"K Krennhrubec","year":"2007","unstructured":"Krennhrubec, K., Marshall, B. L., Hedglin, M., Verdin, E. & Ulrich, S. M. Design and evaluation of \u2018Linkerless\u2019 hydroxamic acids as selective HDAC8 inhibitors. Bioorg. Med. Chem. Lett. 17, 2874\u20132878, https:\/\/doi.org\/10.1016\/j.bmcl.2007.02.064 (2007).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"53376_CR18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/leu.2008.9","volume":"22","author":"S Balasubramanian","year":"2008","unstructured":"Balasubramanian, S. et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 22, 1026\u20131034, https:\/\/doi.org\/10.1038\/leu.2008.9 (2008).","journal-title":"Leukemia."},{"key":"53376_CR19","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.3390\/ijms12129440","volume":"12","author":"S Thangapandian","year":"2011","unstructured":"Thangapandian, S., John, S., Lee, Y., Kim, S. & Lee, K. W. Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery. Int. J. Mol. Sci. 12, 9440\u20139462, https:\/\/doi.org\/10.3390\/ijms12129440 (2011).","journal-title":"Int. J. Mol. Sci."},{"key":"53376_CR20","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1016\/j.bmcl.2003.09.048","volume":"13","author":"T Suzuki","year":"2003","unstructured":"Suzuki, T. et al. Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-based non-hydroxamates. Bioorg. Med. Chem. Lett. 13, 4321\u20134326, https:\/\/doi.org\/10.1016\/j.bmcl.2003.09.048 (2003).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"53376_CR21","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1016\/j.bmc.2013.06.009","volume":"21","author":"T Feng","year":"2013","unstructured":"Feng, T. et al. Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2). Bioorg. Med. Chem. 21, 5339\u20135354, https:\/\/doi.org\/10.1016\/j.bmc.2013.06.009 (2013).","journal-title":"Bioorg. Med. Chem."},{"key":"53376_CR22","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1038\/s41418-018-0080-0","volume":"25","author":"J Shen","year":"2018","unstructured":"Shen, J. et al. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment. Cell Death Differ. 25, 2053\u20132070, https:\/\/doi.org\/10.1038\/s41418-018-0080-0 (2018).","journal-title":"Cell Death Differ."},{"key":"53376_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10822-010-9322-z","volume":"24","author":"PR Murumkar","year":"2010","unstructured":"Murumkar, P. R., Zambre, V. P. & Yadav, M. R. Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors. J. Comput. Aided Mol. Des 24, 143\u2013156, https:\/\/doi.org\/10.1007\/s10822-010-9322-z (2010).","journal-title":"J. Comput. Aided Mol. Des"},{"key":"53376_CR24","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1016\/j.ejmech.2010.07.042","volume":"45","author":"AM Almerico","year":"2010","unstructured":"Almerico, A. M., Tutone, M. & Lauria, A. 3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors. Eur. J. Med. Chem. 45, 4774\u20134782, https:\/\/doi.org\/10.1016\/j.ejmech.2010.07.042 (2010).","journal-title":"Eur. J. Med. Chem."},{"key":"53376_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jmgm.2009.04.006","volume":"28","author":"FA Pasha","year":"2009","unstructured":"Pasha, F. A., Muddassar, M., Neaz, M. M. & Cho, S. J. Pharmacophore and docking-based combined in-silico study of KDR inhibitors. J. Mol. Graph. Model. 28, 54\u201361, https:\/\/doi.org\/10.1016\/j.jmgm.2009.04.006 (2009).","journal-title":"J. Mol. Graph. Model."},{"key":"53376_CR26","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1016\/j.ejmech.2010.06.034","volume":"45","author":"MA Al-Sha\u2019er","year":"2010","unstructured":"Al-Sha\u2019er, M. A. & Taha, M. O. Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur. J. Med. Chem. 45, 4316\u20134330, https:\/\/doi.org\/10.1016\/j.ejmech.2010.06.034 (2010).","journal-title":"Eur. J. Med. Chem."},{"key":"53376_CR27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1021\/ci800366f","volume":"49","author":"H Tang","year":"2009","unstructured":"Tang, H. et al. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation. J. Chem. Inf. Model. 49, 461\u2013476, https:\/\/doi.org\/10.1021\/ci800366f (2009).","journal-title":"J. Chem. Inf. Model."},{"key":"53376_CR28","doi-asserted-by":"publisher","first-page":"7978","DOI":"10.1021\/jm300521m","volume":"55","author":"J Wang","year":"2012","unstructured":"Wang, J. et al. Pharmacophore-Based Virtual Screening and Biological Evaluation of Small Molecule Inhibitors for Protein Arginine Methylation. J. Med. Chem. 55, 7978\u20137987, https:\/\/doi.org\/10.1021\/jm300521m (2012).","journal-title":"J. Med. Chem."},{"key":"53376_CR29","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/DDDT.S62921","volume":"8","author":"C Chen","year":"2014","unstructured":"Chen, C. et al. Drug Design, Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity. Drug Des. Devel. Ther. 8, 1195\u20131210, https:\/\/doi.org\/10.2147\/DDDT.S62921 (2014).","journal-title":"Drug Des. Devel. Ther."},{"key":"53376_CR30","doi-asserted-by":"publisher","first-page":"8073","DOI":"10.1021\/jm4011302","volume":"56","author":"LR Vidler","year":"2013","unstructured":"Vidler, L. R. et al. Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening. J. Med. Chem. 56, 8073\u20138088, https:\/\/doi.org\/10.1021\/jm4011302 (2013).","journal-title":"J. Med. Chem."},{"key":"53376_CR31","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1016\/j.ejmech.2010.06.024","volume":"45","author":"S Thangapandian","year":"2010","unstructured":"Thangapandian, S., John, S., Sakkiah, S. & Lee, K. W. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design. Eur. J. Med. Chem. 45, 4409\u20134417, https:\/\/doi.org\/10.1016\/j.ejmech.2010.06.024 (2010).","journal-title":"Eur. J. Med. Chem."},{"key":"53376_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/RRMC.S81388","volume":"5","author":"T Debnath","year":"2015","unstructured":"Debnath, T., Majumdar, S., Kalle, A. M., Aparna, V. & Debnath, S. Identification of potent histone deacetylase 8 inhibitors using pharmacophore-based virtual screening, three-dimensional quantitative structure\u2013activity relationship, and docking study. Res. Rep. Med. Chem. 5, 21\u201339, https:\/\/doi.org\/10.2147\/RRMC.S81388 (2015).","journal-title":"Res. Rep. Med. Chem."},{"key":"53376_CR33","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1007\/s12272-015-0705-5","volume":"39","author":"GP Cao","year":"2016","unstructured":"Cao, G. P. et al. QSAR modeling to design selective histone deacetylase 8 (HDAC8) inhibitors. Arch. Pharm. Res. 39, 1356\u20131369, https:\/\/doi.org\/10.1007\/s12272-015-0705-5 (2016).","journal-title":"Arch. Pharm. Res."},{"key":"53376_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bioorg.2014.08.005","volume":"57","author":"U Kulandaivelu","year":"2014","unstructured":"Kulandaivelu, U. et al. Hydroxamates of para-aminobenzoic acid as selective inhibitors of HDAC8. Bioorg. Chem. 57, 116\u2013120, https:\/\/doi.org\/10.1016\/j.bioorg.2014.08.005 (2014).","journal-title":"Bioorg. Chem."},{"key":"53376_CR35","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1016\/j.bmc.2016.09.022","volume":"24","author":"VR Pidugu","year":"2016","unstructured":"Pidugu, V. R., Yarla, N. S., Pedada, S. R., Kalle, A. M. & Satya, A. K. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti-cancer activity. Bioorg. Med. Chem. 24, 5611\u20135617, https:\/\/doi.org\/10.1016\/j.bmc.2016.09.022 (2016).","journal-title":"Bioorg. Med. Chem."},{"key":"53376_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00044-016-1652-5","volume":"25","author":"S Debnath","year":"2016","unstructured":"Debnath, S., Debnath, T., Majumdar, S., Arunasree, M. K. & Aparna, V. A combined pharmacophore modeling, 3D QSAR, virtual screening, molecular docking, and ADME studies to identify potential HDAC8 inhibitors. Med. Chem. Res. 25, 1\u201317, https:\/\/doi.org\/10.1007\/s00044-016-1652-5 (2016).","journal-title":"Med. Chem. Res."},{"key":"53376_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2210\/pdb4BKX\/pdb","volume":"51","author":"CJ Millard","year":"2013","unstructured":"Millard, C. J. et al. The structure of HDAC1 in complex with the dimeric ELM2-SANT domain of MTA1 from the NuRD complex. Mol. Cell. 51, 57\u201367, https:\/\/doi.org\/10.2210\/pdb4BKX\/pdb (2013).","journal-title":"Mol. Cell."},{"key":"53376_CR38","doi-asserted-by":"publisher","DOI":"10.2210\/pdb3MAX\/pdb","author":"RJ Skene","year":"2010","unstructured":"Skene, R. J. & Jennings, A. J. Crystal Structure of Human HDAC2 complexed with an N-(2 aminophenyl) benzamide. RCSB Protein Data Bank. https:\/\/doi.org\/10.2210\/pdb3MAX\/pdb (2010).","journal-title":"RCSB Protein Data Bank"},{"key":"53376_CR39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nature10728","volume":"481","author":"PJ Watson","year":"2012","unstructured":"Watson, P. J., Fairall, L., Santos, G. M. & Schwabe, J. W. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature. 481, 335\u201340, https:\/\/doi.org\/10.1038\/nature10728 (2012).","journal-title":"Nature."},{"key":"53376_CR40","doi-asserted-by":"publisher","unstructured":"Bottomley, M. J., et al Structure of HDAC4 catalytic domain bound to a hydroxamic acid inhibitor. RCSB Protein Data Bank, https:\/\/doi.org\/10.2210\/pdb2VQV\/pdb (2008).","DOI":"10.2210\/pdb2VQV\/pdb"},{"key":"53376_CR41","doi-asserted-by":"publisher","unstructured":"Harding, R. J. et al. Structural Genomics Consortium (SGC). Crystal structure of fragment 3-(3-(pyridin-2-ylmethoxy)quinoxalin-2-yl)propanoic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain. RCSB Protein Data Bank, https:\/\/doi.org\/10.2210\/pdb5WPB\/pdb (2017).","DOI":"10.2210\/pdb5WPB\/pdb"},{"key":"53376_CR42","doi-asserted-by":"publisher","unstructured":"Somoza, J. R. et al. Structure of human HDAC8 complexed with Trichostatin A. RCSB Protein Data Bank, https:\/\/doi.org\/10.2210\/pdb1T64\/pdb (2004).","DOI":"10.2210\/pdb1T64\/pdb"},{"key":"53376_CR43","unstructured":"Versatile generation of accurate 3D molecular models. LigPrep, version 2.6, Schr\u00f6dinger, LLC, https:\/\/www.schrodinger.com\/ligprep (2019)."},{"key":"53376_CR44","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10822-006-9087-6","volume":"20","author":"SL Dixon","year":"2006","unstructured":"Dixon, S. L. et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des. 20, 647\u2013671, https:\/\/doi.org\/10.1007\/s10822-006-9087-6 (2006).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"53376_CR45","first-page":"511","volume":"2","author":"R Veerasamy","year":"2011","unstructured":"Veerasamy, R. et al. Validation of QSAR models \u2013 strategies and importance. Int. J. Drug Des. Discov. 2, 511\u2013519 (2011).","journal-title":"Int. J. Drug Des. Discov."},{"key":"53376_CR46","doi-asserted-by":"publisher","first-page":"9562","DOI":"10.1021\/jm300837y","volume":"55","author":"T Suzuki","year":"2012","unstructured":"Suzuki, T. et al. Rapid Discovery of Highly Potent and Selective Inhibitors of Histone Deacetylase 8 Using Click Chemistry to Generate Candidate Libraries. J. Med. Chem. 55, 9562\u20139575, https:\/\/doi.org\/10.1021\/jm300837y (2012).","journal-title":"J. Med. Chem."},{"key":"53376_CR47","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/cmdc.201300414","volume":"9","author":"T Suzuki","year":"2014","unstructured":"Suzuki, T. et al. Design, Synthesis, and Biological Activity of NCC149 Derivatives as Histone Deacetylase 8-Selective Inhibitors. Chem. Med. Chem. 9, 657\u2013664, https:\/\/doi.org\/10.1002\/cmdc.201300414 (2014).","journal-title":"Chem. Med. Chem."},{"key":"53376_CR48","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1016\/j.bmcl.2011.01.134","volume":"21","author":"W Tang","year":"2011","unstructured":"Tang, W., Luo, T., Greenberg, E. F., Bradner, J. E. & Schreiber, S. L. Discovery of histone deacetylase 8 selective inhibitors. Bioorg. Med. Chem. Lett. 21, 2601\u20132605, https:\/\/doi.org\/10.1016\/j.bmcl.2011.01.134 (2011).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"53376_CR49","unstructured":"Rapid ADME predictions of drug candidates. Qik Prop, Version 3.5, Schrodinger, LLC, New York, https:\/\/www.schrodinger.com\/qikprop (2013)."},{"key":"53376_CR50","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1021\/ci800293n","volume":"9","author":"KE Hevener","year":"2009","unstructured":"Hevener, K. E. et al. Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase. J. Chem. Inf. Model. 9, 444\u2013460, https:\/\/doi.org\/10.1021\/ci800293n (2009).","journal-title":"J. Chem. Inf. Model."},{"key":"53376_CR51","unstructured":"A complete solution for ligand-receptor docking. Glide, version 6.0, Schr\u00f6dinger, LLC, New York, NY, https:\/\/www.schrodinger.com\/glide (2013)"},{"key":"53376_CR52","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739\u20131749, https:\/\/doi.org\/10.1021\/jm0306430 (2004).","journal-title":"J. Med. Chem."},{"key":"53376_CR53","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1021\/jm030644s","volume":"47","author":"TA Halgren","year":"2004","unstructured":"Halgren, T. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47, 1750\u20131759, https:\/\/doi.org\/10.1021\/jm030644s (2004).","journal-title":"J. Med. Chem."},{"key":"53376_CR54","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner, R. A. et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49, 6177\u20136196, https:\/\/doi.org\/10.1021\/jm051256o (2006).","journal-title":"J. Med. Chem."},{"key":"53376_CR55","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1021\/ci900212v","volume":"49","author":"NK Salam","year":"2009","unstructured":"Salam, N. K., Nuti, R. & Sherman, W. Novel Method for Generating Structure-Based Pharmacophores Using Energetic Analysis. J. Chem. Inf. Model. 49, 2356\u20132368, https:\/\/doi.org\/10.1021\/ci900212v (2009).","journal-title":"J. Chem. Inf. Model."},{"key":"53376_CR56","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1021\/ci900212v","volume":"23","author":"K Loving","year":"2009","unstructured":"Loving, K., Salam, N. K. & Sherman, W. Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. J. Comput. Aided Mol. Des. 23, 541\u2013554, https:\/\/doi.org\/10.1021\/ci900212v (2009).","journal-title":"J. Comput. Aided Mol. Des."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53376-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53376-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53376-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:06:59Z","timestamp":1671293219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53376-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["53376"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-53376-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"15 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17174"}}